Concluding remarks: Pursuit of the optimal outcome in hypertension

Clinical Pharmacokinetics

Volumn 37, Issue SUPPL. 1, 1999, Pages 33-38

  Hansson, Lennart ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; INDAPAMIDE; LIPID; POTASSIUM ION;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DRUG EFFICACY; GLUCOSE METABOLISM; HEART; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY; LIPID BLOOD LEVEL; PATIENT MONITORING; POTASSIUM BLOOD LEVEL; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STROKE; SUSTAINED RELEASE FORMULATION; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0032881829     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199937001-00005     Document Type: Review

References (48)

1. Hansson L. Status of current therapies for hypertension. Blood Press 1995; 4 Suppl. 2: 93-8
2. Hansson L. Cardioprotective potential of antihypertensives. Am J Hypertens 1995; 8: 49S-52
3. Hansson L. The benefits of lowering elevated blood pressure: a critical review of studies of cardiovascular morbidity and mortality in hypertension. J Hypertens 1996; 14: 537-44
4. Hansson L. Success in the treatment of hypertension: a status report. J Hypertens 1997; 15 Suppl. 2: S11-15
5. Hansson L. Issues in the treatment of hypertension: current and future perspectives. Cardiology 1997; 88 Suppl. 1: 47-53
6. Forette F, Seux M-L, Staessen JA, et al., on behalf of the Syst-Eur Investigators. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347-51
7. Linjer E, Hansson L. Underestimation of the true benefits of antihypertensive treatment: assessment of some important sources of error. J Hypertens 1997; 15: 221-5
8. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Pt 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-74
9. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med 1993; 153: 598-615
10. Himmelmann A, Hedner T, Hansson L, et al. Isolated systolic hypertension: an important cardiovascular risk factor. Blood Press 1998; 7: 197-207
11. Jackson R. Which elderly patients should be considered for anti-hypertensive treatment? An evidence-based approach. J Hum Hypertens 1998; 12: 607-13
12. Ramsay LE, Wallis EJ, Yeo WW, et al. The rationale for differing national recommendations for the treatment of hypertension. Am J Hypertens 1998; 11: 79S-88
13. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure, The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC-V). Arch Intern Med 1993; 153: 154-83
14. Joint National Committee, on Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-46
15. WHO - ISH Guidelines Committee. Guidelines for the management of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension meeting. J Hypertens 1993; 11: 905-18
16. Sever P, Beevers G, Bulpitt C, et al. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ 1993; 306: 983-7
17. Jackson R, Barham P, Bills J, et al. The management of raised blood pressure in New Zealand. BMJ 1993; 307: 107-10
18. Weber MA, Radensky P. Measurement of short-term, intermediate, and long-term outcomes of treating hypertension. Cardiol Clin 1996; 14: 131-42
19. Hansson L. Evaluation of endpoints in hypertension. Blood Press 1997; 6 Suppl. 2; 76-80
20. Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97: 48-54
21. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Pt 2. Short-term reductions in blood pressure; overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-38
22. Hansson L. The optimal blood pressure reduction. J Hypertens 1996; 14 Suppl. 2: S55-59
23. Hansson L, Zanchetti A, Carruthers SG, et al., for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial, Lancet 1998; 351: 1755-62
24. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13
25. Tuomilehto J, Rastenyte D, Birkenhäger WH, et al., for the Systolic Hypertension in Europe Trial Investigators. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999; 340: 677-84
26. Guidelines Subcommittee. 1999 World Health Organization -International Society of Hypertension guidelines for the management of hypertension. Blood Press 1999; 8 Suppl. 1: 1-36
27. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997; 277: 739-45
28. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group, Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-64
29. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405-12
30. Neaton JD, Grimm Jr RH, Prineas RJ, et al. for the Treatment of Mild Hypertension Study Research Group. Treatment of Mild Hypertension Study. Final results. JAMA 1993; 270: 713-24
31. Moser M. Why are physicians not prescribing diuretics more frequently in the management of hypertension? JAMA 1998; 279: 1813-6
32. Black HR. The evolution of low-dose diuretic therapy: the lessons from clinical trials. Am J Med 1996; 101 Suppl. 3A: 47S-52
33. Weir MR, Flack JM, Appelgate WB. Tolerability, safety and quality of life and hypertensive therapy: the case for low-dose diuretics. Am J Med 1996; 101 Suppl. 3A; 83S-92
34. Flack JM, Cushman WC. Evidence for the efficacy of low-dose diuretic monotherapy. Am J Med 1996; 101 Suppl. 3A: 53S-60
35. Moser M, Hebert PR, Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996; 27: 1214-8
36. Gottdiener JS, Reda DJ, Massie BM, et al. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation 1997; 95: 2007-14
37. Neutel JM, Metabolic manifestations of low-dose diuretics. Am J Med 1996; 101 Suppl. 3A: 71S-82
38. Teuscher AU, Weidmann PU. Requirements tor antihypertensive therapy in diabetic patients. J Hypertens 1997; 15 Suppl. 2: S67-75
39. Ames RP. A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides. Am J Cardiol 1996; 77: 12B-16
40. Madkour H, Gadallah M, Riveline B, et al. Indapamide is superior to thiazide in the preservation of renal function in patients with renal insufficiency and systemic hypertension. Am J Cardiol 1996; 77: 23B-25
41. Carey PA, Sheridan DJ, de Cordoue A, et al. Effect of indapamide on left ventricular hypertrophy in hypertension: a meta-analysis. Am J Cardiol 1996; 77: 17B-19
42. Damien G, Huet de Barochez B, Schiavi P, Galenic development and pharmacokinetic profile of indapamide sustained release 1.5mg. Clin Pharmacokinet 1999; 37 Suppl. 1: 13-19
43. Guez D, Mallion J-M, Degaute J-P, et al. Traitment de l'hypertension artérielle par l'indapamide 1,5 mg comprimé enrobé à libération prolongée: synthèse des résultats. Arch Mal Coeur 1996; 89: 17-25
44. Asmar R, Résultats d'efficacité et de sécurité d'indapamide 1,5 mg comprimé enrobé à libération prolongée dans le traitment de l'hypertension artérielle. Ann Cardiol Angéiol 1998; 47: 94-104
45. Ambrosioni E, Safar M, Degaute J-P, et al. Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomised double-blind controlled studies. J Hypertens 1996; 16: 1677-84
46. Donnelly R. Clinical implications of indapamide sustained release 1.5mg in hypertension. Clin Pharmacokinet 1999; 37 Suppl. 1:21-32
47. Bulpitt CJ, Emeriau JP, Knauf H, et al. Equivalence study of antihypertensive effect of indapamide sustained-release (SR) 1.5 mg, hydrochlorothiazide 25 mg and amlodipine 5 mg in hypertension [abstract]. J Hypertens 1997; 15 Suppl. 4: S-130
48. Gosse P, Dubourg O, Gueret P, et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1,5 versus enalapril 20mg: results of LIVE study [abstract]. J Am Coll Cardiol 1999; 33: 246A